Article
Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Aug 2015
Bidard F-C, Ng C K Y, Cottu P, Piscuoglio S, Escalup L, Sakr R A, Reyal F, Mariani P, Lim R, Wang L, Norton L, Servois V, Sigal B, Vincent-Salomon A, Weigelt B, Pierga J-Y, Reis-Filho J S
Abstract excerpt
BACKGROUND: HER3 activating mutations have been shown in preclinical models to be oncogenic and ligand-independent, but to depend on kinase-active HER2. PATIENTS AND METHODS: Whole-exome sequencing of the primary HER2-negative breast cancer and its HER2-negative synchronous liver metastasis from a 46-year-old female revealed the presence of an activating and clonal HER3 G284R mutation. RESULTS: HER2 dual blockade...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.